An experimental treatment, gantenerumab, failed to help people at high risk of memory loss from Alzheimer’s or those who were in the early phases of the disease, the manufacturer said Monday.
Related Posts
CDC issues alert over rising measles cases in the U.S.
The CDC on Monday warned doctors about an increase
10 doctors on FDA panel for Abbott heart device had financial ties to the company
When a group of FDA advisors recently assessed a h